The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II randomized controlled trial (RCT) of medical intensive nutrition therapy (MINT) to improve chemotherapy (CT) tolerability in malnourished patients with solid tumor malignancies.
 
Michael Shusterman
No Relationships to Disclose
 
Gagandeep Brar
No Relationships to Disclose
 
Kelsey Klute
Consulting or Advisory Role - Bayer
Research Funding - Abbvie; Pharmacyclics
 
Victoria Cooley
No Relationships to Disclose
 
Alexandra Rosenstock
No Relationships to Disclose
 
Eun Kyeong Hwang
No Relationships to Disclose
 
Dina Elmonshed
No Relationships to Disclose
 
Joseph T. Ruggiero
No Relationships to Disclose
 
Allyson J. Ocean
Consulting or Advisory Role - Celgene; Tyme
Speakers' Bureau - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Elizabeta C. Popa
No Relationships to Disclose
 
Scott T. Tagawa
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bayer; Clovis Oncology; Dendreon; Endocyte; Genentech; Genomic Health; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics; Telix Pharmaceuticals
 
Ana M. Molina
Honoraria - ASCO
Consulting or Advisory Role - Eisai; Eisai; Eisai; Exelixis; Janssen; Novartis
 
David M. Nanus
Consulting or Advisory Role - Roche/Genentech
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Immumedics (Inst); Janssen (Inst); Novartis (Inst); pfizer (Inst); Zenith Epigenetics (Inst)
 
Ronald J. Scheff
Honoraria - AstraZeneca; Boehringer Ingelheim
Consulting or Advisory Role - Boehringer Ingelheim; Lilly
Research Funding - AstraZeneca; AstraZeneca; Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim
 
Ashish Saxena
Honoraria - AstraZeneca; Genentech/Roche; Medtronic
Consulting or Advisory Role - AstraZeneca; Takeda
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Endocyte (Inst); Genentech (Inst); Guardant Health (Inst); Immunomedics (Inst); Jounce Therapeutics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Novocure (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Medtronic; Takeda
 
Marcus D. Goncalves
No Relationships to Disclose
 
Paul J. Christos
No Relationships to Disclose
 
Manish A. Shah
Consulting or Advisory Role - Astellas Pharma; Lilly Japan
Research Funding - Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Merck (Inst); Oncolys BioPharma (Inst)